Kyowa Kirin Co Ltd
TSE:4151
Kyowa Kirin Co Ltd
Cash & Cash Equivalents
Kyowa Kirin Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kyowa Kirin Co Ltd
TSE:4151
|
Cash & Cash Equivalents
¥244.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
64%
|
CAGR 10-Years
28%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash & Cash Equivalents
¥494.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash & Cash Equivalents
¥682.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cash & Cash Equivalents
¥426.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash & Cash Equivalents
¥393.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cash & Cash Equivalents
¥179.9B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.
See Also
What is Kyowa Kirin Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
244.7B
JPY
Based on the financial report for Dec 31, 2024, Kyowa Kirin Co Ltd's Cash & Cash Equivalents amounts to 244.7B JPY.
What is Kyowa Kirin Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
28%
Over the last year, the Cash & Cash Equivalents growth was -39%. The average annual Cash & Cash Equivalents growth rates for Kyowa Kirin Co Ltd have been -10% over the past three years , 64% over the past five years , and 28% over the past ten years .
You don't have any saved screeners yet